US Stock MarketDetailed Quotes
HLVX HilleVax
- 1.600
- -0.060-3.61%
Close Aug 9 16:00 ET
- 1.660
- +0.060+3.75%
Post 17:36 ET
79.66MMarket Cap-473P/E (TTM)
1.770High1.590Low751.94KVolume1.770Open1.660Pre Close1.22MTurnover4.04%Turnover RatioLossP/E (Static)49.78MShares20.22052wk High0.39P/B29.82MFloat Cap1.55052wk Low--Dividend TTM18.64MShs Float24.420Historical High--Div YieldTTM10.84%Amplitude1.550Historical Low1.621Avg Price1Lot Size
HilleVax Stock Forum
Sign in to post a comment
$HilleVax (HLVX.US)$ fly to the moon 🌙
2
1
$HilleVax (HLVX.US)$ recovery sure would happen, how much would it pull up??
HilleVax, Inc. Announced Disappointing Results from NEST-IN1 Clinical Study.
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further dev...
On a day that saw its stock plummet by 84%, closing at $2.25, HilleVax, Inc. (Nasdaq: HLVX) announced the topline data results from its NEST-IN1 clinical study. This notable decline followed the announcement that the NEST-IN1 study did not meet its primary or secondary efficacy endpoints, leading the company to discontinue further dev...
$HilleVax (HLVX.US)$
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax wil...
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax announced topline results from the NEST-IN1 Phase 2b study of HIL-214 in infants. The trial, conducted in the US and Latin America, did not meet its primary or secondary efficacy endpoints. Specifically, the vaccine showed a mere 5% efficacy against moderate or severe acute gastroenteritis caused by norovirus, which was statistically insignificant. Consequently, HilleVax wil...
how the F they gonna cut the target from 28 down to 2 just because of failed trial? This company has pretty sound finances and their debt to assets is extremely good for this particular field
2
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$HilleVax (HLVX.US)$ friday usd 1.10
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Ziggz420 : $ARCA biopharma (ABIO.US)$ still in it
silverelf Ziggz420 : Same![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")